Human Platelet Lysate Market Forecasts to 2030 – Global Analysis By Drug Type (Heparin-based Human Platelet Lysate, Heparin-free Human Platelet Lysate and Other Types), Route of Administration (Oral, Inhalational and Other Routes of Administration), Distribution Channel, End User and By Geography
According to Stratistics MRC, the Global Human Platelet Lysate Market is accounted for $53.75 million in 2023 and is expected to reach $80.29 million by 2030 growing at a CAGR of 5.9% during the forecast period. Human Platelet Lysate (HPL) is a cell culture supplement derived from human blood platelets. It contains growth factors like platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), and various other proteins that promote cell survival and stimulate tissue regeneration. Moreover, it offers numerous advantages over traditional cell culture supplements like foetal bovine serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.
According to data published on National Library of Medicine, stated that human platelet lysate (hPL) has higher production cost than foetal bovine serum, which is an alternative option of human platelet lysate (hPL).
Market Dynamics:Driver:Increasing demand in cell culture applications
Human platelet lysate, renowned for its rich composition of growth factors and cytokines essential for cell growth and proliferation, has emerged as a superior alternative to traditional serum-based media. Its ability to support cell expansion, maintain cellular properties, and promote tissue regeneration has led to increased adoption in regenerative medicine, stem cell research, and tissue engineering. Moreover, the heightened focus on personalised medicine, cell-based therapies, and advancements in drug discovery utilising cell cultures further amplifies the need for human platelet lysate. Therefore, it will propel market growth.
Restraint:High production costs
The complex manufacturing process involving the collection, processing, and quality control measures for human platelet lysate results in elevated production expenses compared to traditional serum-based media. These higher costs limit its affordability and accessibility for widespread commercial use in cell culture applications, potentially hindering its adoption. As a result, it will hamper market expansion.
Opportunity:Advancements in regenerative medicine
The human platelet lysate's rich composition of growth factors and cytokines essential for cell growth and tissue regeneration aligns perfectly with the requirements of regenerative therapies. As regenerative medicine continues to evolve, HPL emerges as a crucial supplement in cell culture, supporting cell proliferation and maintaining cellular properties necessary for tissue regeneration. Furthermore, its ability to enhance wound healing, stimulate tissue repair, and aid in the development of cell-based therapies positions human platelet lysate as a valuable component in regenerative medicine applications.
Threat:Contamination risks
Despite reduced xenogeneic contamination compared to foetal bovine serum (FBS), human platelet lysate carries the potential risk of pathogen transmission from human-derived products. Contaminants, such as bacteria or viruses, could compromise the quality and safety of human platelet lysate, impacting its suitability for cell culture applications in research and clinical settings. Hence, it acts as a significant barrier to market expansion.
Covid-19 ImpactThe COVID-19 pandemic initially caused disruptions in the healthcare sector and restrictions on blood donations, which affected the availability of raw materials for HPL production. Supply chain disruptions and reduced laboratory activities hindered its manufacturing and distribution. However, the pandemic underscored the importance of cell-based therapies, boosting interest in regenerative medicine and cell culture applications where HPL plays a crucial role. As the healthcare sector adapted, the market witnessed a resurgence due to increased research focus on cell-based treatments, potentially driving further demand for HPL.
The heparin-based human platelet lysate segment is expected to be the largest during the forecast period
The heparin-based human platelet lysate segment is estimated to hold the largest share. Heparin serves to prevent clotting during platelet collection and HPL production, ensuring the maintenance of platelet integrity and bioactivity. This specialised variant of HPL offers advantages in cell culture applications by supporting cell growth, proliferation, and viability. The inclusion of heparin enhances the functionality of HPL, making it particularly beneficial in various biomedical fields, including regenerative medicine, stem cell research, and tissue engineering, where uninterrupted platelet bioactivity is essential for optimal cell culture outcomes.
The hospital pharmacies segment is expected to have the highest CAGR during the forecast period
The hospital pharmacies segment is anticipated to have lucrative growth during the forecast period. Hospital pharmacies serve as crucial intermediaries, providing human platelet lysate products to healthcare facilities, clinicians, and researchers. These pharmacies play a pivotal role in supplying human platelet lysate for various medical applications, including regenerative medicine, cell therapy, and research endeavours. Moreover, they ensure the availability, quality, and timely distribution of human platelet lysate products, facilitating their use in clinical settings and research laboratories within hospitals.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period due to rising biomedical research activities, increasing investments in regenerative medicine, and a growing focus on cell-based therapies. Countries such as China, Japan, South Korea, and India are prominent contributors to HPL market growth, leveraging advancements in healthcare infrastructure and research initiatives. Furthermore, the region's burgeoning biopharmaceutical industry, combined with the emphasis on personalised medicine and regenerative therapies, offers substantial opportunities for HPL adoption, shaping the Asia-Pacific region as a significant hub for HPL utilisation in diverse biomedical applications.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period due to advanced healthcare infrastructure, a robust biopharmaceutical industry, and substantial investments in biomedical research. Growing emphasis on personalised medicine and the escalating demand for cell-based therapies bolster the utilisation of HPL in various biomedical applications. Furthermore, North America stands as a key region, characterised by its cutting-edge developments and a strong foundation for the widespread adoption of HPL in biomedical research and clinical settings.
Key players in the market
Some of the key players in the Human Platelet Lysate Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Glenmark Pharmaceuticals Limited, Dabur India Ltd, Johnson and Johnson, Glenmark Pharmaceuticals Limited, Merck KGaA, Pfizer Inc., Novartis International AG, Sanofi SA, Vernalis plc, Aurobindo Pharma Ltd, The Himalaya Drug Company, Beckman Coulter Inc., Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC, Acadia Pharmaceuticals Inc. and Biocon.
Key Developments:In June 2023, PL BioScience GmbH entered into a Patent License and Assignment Agreement with French company Macopharma S.A.S., granting PL BioScience a worldwide license under Macopharma's patents and introducing PL BioScience to Macopharma's HPL customers for future orders.
In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.
In June 2021, Captivate Bio has signed a partnership agreement with PL BioScience GmbH to exclusively distribute ELAREM human platelet lysate products in the US and Canada, expanding their HPL offerings and enhancing PL BioScience's market presence in North America.
Drug Types Covered:
• Heparin-based Human Platelet Lysate
• Heparin-free Human Platelet Lysate
• Other Types
Route of Administrations Covered:
• Oral
• Inhalational
• Other Routes of Administration
Distribution Channels Covered:
• Hospital Pharmacies
• Drug Store
• Retail Store
• Online Pharmacies
End Users Covered:
• Therapeutic
• Pharmaceutical and Biotechnology Companies
• Research and Academic Institutions
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements